Therapeutic reactive oxygen generation.
An increase of the intracellular reactive oxygen species (ROS) concentration leads to the development of oxidative stress and, thus, to the damage of cell components. The cause-and-effect relations between these processes have not been fully established yet. The ability of photo excited supramolecular composites containing fullerenes C60 immobilized at nanosilica particles to generate reactive oxygen species (ROS) in cells of two types (rat thymocytes, and transformed cells of ascite Erlich carcinoma, EAC, and leucosis L1210) is demonstrated. The damaging effect of photo excited C60-composites are shown, which appeared to be selective and manifested in transformed cells, but not in thymocytes. It has been shown that after the irradiation of aqueous solutions or cell suspensions in the presence of fullerene C60, the generation of reactive oxygen species is observed. It has been shown that the influence of photo excited fullerene C60 on metabolic processes depends on the composition of C60-containing complex and on the type of the cells. The damaging effects of photo excited fullerene C60-containing composites were demonstrated to be selective. The data presented suggest that the application of fullerene C60-containing composites for the selective activation of ROS-dependent death program in certain types of tumor cells is very promising.
Technische Universität Ilmenau, Institute of Physics, Ilmenau, Germany. peter.scharff@tu-ilmenau.de
Peter
P
Scharff
Uwe
U
Ritter
Olga P
OP
Matyshevska
Svitlana V
SV
Prylutska
Iryna I
II
Grynyuk
Alexandr A
AA
Golub
Yuriy I
YI
Prylutskyy
Anatoliy P
AP
Burlaka
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy; D002470:Cell Survival / Q000187:drug effects*; D037741:Fullerenes / Q000494:pharmacology* / Q000627:therapeutic use; D007939:Leukemia L1210 / Q000188:drug therapy; D053761:Nanocomposites; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D010778:Photochemotherapy / Q000379:methods*; D051381:Rats; D017208:Rats, Wistar; D017382:Reactive Oxygen Species / Q000494:pharmacology* / Q000627:therapeutic use; D012822:Silicon Dioxide; D013950:Thymus Gland / Q000166:cytology*
D000970:Antineoplastic Agents; D037741:Fullerenes; D017382:Reactive Oxygen Species; D012822:Silicon Dioxide; C069837:fullerene C60